Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection

Pediatrics

Volumn 112, Issue 1 I, 2003, Pages 66-73

  Nachman, Sharon ^a   Kim, Soyeon ^b   King, James ^c   Abrams, Elaine J ^d   Margolis, David ^e   Petru, Ann ^f   Shearer, William ^g   Smith, Elizabeth ^h   Moye, Jack ⁱ   Blanchard, Suzette ^j   Hawkins, Elizabeth ^k   Bouquin, Pamela ^j   Vink, Peter ^l   Benson, Mindy ^m   Estep, Scharla ^h   Malinoski, Frank ⁿ  

^a STONY BROOK UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f CHILDREN S HOSPITAL OAKLAND   (United States)

^g TEXAS CHILDREN S HOSPITAL   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^j FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^k Pediatric ACTG Operations Center   (United States)

^l UNIVERSITY OF MARYLAND   (United States)

^m SAN FRANCISCO GENERAL HOSPITAL   (United States)

ⁿ Lederle Praxis Biologicals   (United States)

more..

Author keywords

Heptavalent pneumococcal conjugate vaccine; HIV; Immunogenicity; Pneumococcal polysaccharide vaccine; Prevnar; Safety

Indexed keywords

ANTIRETROVIRUS AGENT; IMMUNOGLOBULIN G ANTIBODY; PLACEBO; PNEUMOCOCCUS VACCINE;

AGE; ANEMIA; APNEA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFANT; MALE; MORTALITY; OTITIS MEDIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SAFETY; SINGLE BLIND PROCEDURE; SPLENOMEGALY; STREPTOCOCCUS INFECTION; WHEEZING;

ANTIBODIES, BACTERIAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOCOMPETENCE; IMMUNOGLOBULIN G; INFANT; MALE; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RISK; SAFETY; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0037743433     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.112.1.66     Document Type: Article

References (17)

1. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 1998;101:604-611
2. Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 1999;18:757-763
3. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:183-186
4. American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: recommendation for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362-366
5. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2000;49:1-38
6. Dankner WM, Lindsey JC, Levin MJ. CD4 correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J. 2001;20:40-48
7. Danker W, Levin M, Nachman S, et al. Rates of opportunistic infections in HIV-infected children on Pediatric AIDS Clinical Trials Group treatment protocols in the post-protease inhibitor era. PACTG meetings, July 2001
8. Farley JJ, King JC, Nair P, et al. Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection. J Pediatr. 1994;124:853-858
9. Andiman WA, Mezger I, Shapiro E. Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1. J Pediatr. 1994;124:846-852
10. Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs) report, emerging infections program network, Streptococcus Pneumoniae. 1997-2000. Available at: www.cdc.gov/ncidod/dbmd/abcs
11. Quataert SA, Kirch CS, Wiedle LJ, et al. Assignment of weight-based antibody units to a human anti-pneumococci standard reference serum, lot 89-S. Clin Diagn Lab Immunol. 1995;2:590-597
12. Quataert S, Martin D, Anderson P, et al. A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides. Immunol Invest. 2001;30:191-297
13. Orange M, Gray B. Pneumococcal serotypes causing disease in children in Alabama. Pediatr Infect Dis J. 1993;12:244-245
14. Ahman H, Kayhty H, Tamminen P, et al. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis. 1996;2:134-139
15. Eskola J. Immunogenicity of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2000;19:388-393
16. Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30:100-121.
17. Feikin D, Elie C, Goetz M, et al. Immunologic and virologic response to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults [abstract 48]. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2000